Cenerimod + Placebo
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nephritis, Lupus
Conditions
Nephritis, Lupus, Lupus Erythematosus, Systemic
Trial Timeline
Feb 9, 2026 → Feb 1, 2030
NCT ID
NCT07201129About Cenerimod + Placebo
Cenerimod + Placebo is a phase 3 stage product being developed by Viatris for Nephritis, Lupus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07201129. Target conditions include Nephritis, Lupus, Lupus Erythematosus, Systemic.
What happened to similar drugs?
1 of 20 similar drugs in Nephritis, Lupus were approved
Approved (1) Terminated (8) Active (12)
❌tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisoneAstellas PharmaPhase 3
🔄HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07201129 | Phase 3 | Recruiting |
| NCT05672576 | Phase 3 | Active |
| NCT05648500 | Phase 3 | Recruiting |
Competing Products
20 competing products in Nephritis, Lupus